There are roughly 77 million baby boomers living in the U.S. right now, and for some, a need for greater healthcare is just over the horizon. In other words, healthcare is where all the growth is these days, and that's why Cramer took a closer look at Celgene on Thursday.
While most big-name pharmaceutical brands are dealing with major patent blockades and most smaller single-drug companies "might as well be lottery tickets on the FDA approval process," Celgene falls somewhere safely in-between the two extremes.
The biotech giant already has plenty of blockbuster drugs on the market, a diverse array of products still in the works and an unparalleled overall revenue growth of 40 percent. Over the past 15 years, the company's stock has shot up 8,936 percent and yet, Cramer still thinks it has room to run.
Celgene's focus for right now is on Revlimid for multiple myeloma, a rare cancer of the plasma cells in bone marrow. If all goes well for the firm, Revlimid has the potential to rake in $4 billion in annual sales by the year 2013. But the stock's real future, Cramer said, depends on what else lies in the pipeline and what other progress we can expect to see.
To learn more about the company's future path and trajectory, Cramer chatted with Celgene Chairman and CEO Bob Hugin. To see the full interview, watch the video.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website? email@example.com